ImmuCell (ICCC) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on ImmuCell (ICCC) is Neutral.

The composite score behind that read is -0.01, weighing +0.22 of bullish evidence against -0.27 bearish.

ImmuCell last closed at $9.80, +0.51% on the session.

Against the IVW growth benchmark the position is -0.29% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

19 graded predictions for ICCC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks ImmuCell in the 5th percentile on valuation and the 44th percentile on return on equity, where 100 is best.

ImmuCell is classified under Health Care / Biotechnology, with a market capitalisation of $88.55M.

StockMap tracks ImmuCell as the 289th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite ImmuCell ranks 112th of 381 in the group, against a group median of -0.08.